Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketorolac/phenylephrine - Omeros Corporation

Drug Profile

Ketorolac/phenylephrine - Omeros Corporation

Alternative Names: Omidria; OMS-302; OMS-302-PE; Phenylephrine and ketorolac intraocular solution; Phenylephrine/ketorolac

Latest Information Update: 25 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Omeros Corporation
  • Class Analgesics; Anti-inflammatories; Antihypotensives; Decongestants; Ethanolamines; Eye disorder therapies; Indoles; Mydriatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Miosis; Postoperative pain

Most Recent Events

  • 24 May 2018 Omeros Corporation enters into a settlement agreement with Lupin and its subsidiary Lupin Pharmaceuticals, resolving Omeros’ patent litigation against Lupin's filing of an ANDA seeking approval from the US FDA to market a generic version of ketorolac/phenylephrine
  • 12 Dec 2017 Registered for Miosis (In adolescents, In children, In infants, In neonates, Prevention) in USA (Intraocular)
  • 12 Dec 2017 Registered for Postoperative pain (In adolescents, In children, In infants, In neonates) in USA (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top